CLAIMS

1. Use of resmetirom or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating nonalcoholic steatohepatitis (NASH) in a human subject:

wherein resmetirom is to be administered as a solid oral dosage form, the solid oral dosage form comprising:

(i) resmetirom or a pharmaceutically acceptable salt thereof at a dosage of 100 mg per day, if the human subject is determined to weigh 100 kg or more; or

(ii) resmetirom or the pharmaceutically acceptable salt thereof at a dosage of 80 mg per day, if the human subject is determined to weigh less than 100 kg.

2. The use according to claim 1, wherein the human subject is determined to weigh 100 kg or more and the solid oral dosage form comprising resmetirom or the pharmaceutically acceptable salt thereof is to be adminstered at the dosage of 100 mg per day.

3. The use according to claim 1, wherein the human subject is determined to weigh less than 100 kg and the solid oral dosage form comprising resmetirom or the pharmaceutically acceptable salt thereof is to be administered at the dosage of 80 mg per day.

4. The use according to any one of the preceding claims, wherein the use is for treating noncirrhotic nonalcoholic steatohepatitis with moderate to advanced liver fibrosis consistent with stages F2 to F3.

5. The use according to any one of the preceding claims, wherein the use is for improving noncirrhotic nonalcoholic steatohepatitis.

6. The use according to any one of the preceding claims, wherein the solid oral dosage form comprises resmetirom.

7. Use of resmetirom or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating liver fibrosis in a human subject:

wherein resmetirom is to be administered as a solid oral dosage form, the solid oral dosage form comprising:

(i) resmetirom or a pharmaceutically acceptable salt thereof at a dosage of 100 mg per day, if the human subject is determined to weigh 100 kg or more; or

(ii) resmetirom or the pharmaceutically acceptable salt thereof at a dosage of 80 mg per day, if the human subject is determined to weigh less than 100 kg; and

wherein the human subject has liver fibrosis associated with nonalcoholic steatohepatitis (NASH).

8. The use according to claim 7, wherein the use is for improving the liver fibrosis.

9. The use according to claim 7 or 8, wherein the use is for treating liver fibrosis characterized as: (i) fibrosis stage F2; or (ii) fibrosis stage F3.

10. The use according to any one of claims 8-9, wherein the use is for improving the liver fibrosis by one stage in the human subject.

11. The use according to claim 9, wherein the use is for improving the liver fibrosis characterized as fibrosis stage F3 by two stages in the human subject.

12. The use according to any one of claims 7-11, wherein:

(i) the human subject is determined to weigh 100 kg or more and the solid oral dosage form comprising resmetirom or the pharmaceutically acceptable salt thereof is to be administered at the dosage of 100 mg per day; or

(ii) the human subject is determined to weigh less than 100 kg and the solid oral dosage form comprising resmetirom or the pharmaceutically acceptable salt thereof is to be administered at the dosage of 80 mg per day.

13. The use according to any one of claims 7-12, wherein the solid oral dosage form comprises resmetirom.

14. The use according to any one of claims 1-13, wherein the solid oral dosage form is a tablet.

15. The use according to any one of claims 1-14, wherein the human subject is an adult human subject.